AstraZeneca PLC (LSE:AZN) - Share price

Stock Report

AstraZeneca PLC AZN

Last Price

Day Change

As of 22/10/2021
17:48:49 BST | GBX
Minimum 15 Minutes Delay.

Last Close8,863.00p
Day Range8,873.00 - 9,029.00
Mkt Cap139.40Bil
52-Wk Range6,499.80 - 9,081.00
Yield %2.28

Share Price

Total Returns 22/10/2021

 Chg (%)  
More ...
AstraZeneca PLC7.11 
FTSE 100 TR GBP4.64
More ...
Income Statement
Operating Profit516.00690.003,694.00
Net Profit2,050.001,227.003,144.00
Reported EPS1.701.032.44
Balance Sheet
Current Assets14,609.0015,493.0019,544.00
Non Current Assets45,060.0045,814.0047,185.00
Total Assets60,651.0061,377.0066,729.00
Current Liabilities16,292.0018,117.0020,307.00
Total Liabilities46,607.0046,781.0051,091.00
Total Equity14,044.0014,596.0015,638.00
Cash Flow
Operating Cash Flow3,155.004,087.006,361.00
Net Change in Cash1,537.00547.002,311.00

Regulatory News

DateAuthor Headline
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech
29/10/2019James Gard Brexit Investment Strategies for Uncertain Times
With a General Election slated for December and Brexit postponed until 2020, investors should consider how their portfolios are positioned for more months of uncertainty 
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete
Director Dealings
More ...
16/12/2020PurchaseMr. Philip A J Broadley7,625.001,31099,888.00
16/12/2020PurchaseProfessor Nazneen Rahman7,679.0025819,812.00
16/12/2020PurchaseProfessor Nazneen Rahman7,678.0025919,886.00

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue.


Drug Manufacturers - General


FTSE 100 , FTSE 350 , FTSE All Share , FTSE Eurotop 100 , FTSE Eurotop 300

Next Event 12/11/2021

Third Quarter Results
More ...
PER (E)41.91
Div Yld (E)2.26
PEG (E)1.02
Op Mrgn0.14
EPS Grwth0.00
More ...
Record Date26/02/2113/08/21
More ...
Non-Executive DirectorMs. Sherilyn S. McCoy
Non-Executive Director, ChairmanMr. Leif Johansson
Executive Director, Chief Financial OfficerMr. Marc Dunoyer
Non-Executive DirectorMr. Marcus Wallenberg
Non-Executive DirectorMr. Michel Demare
Executive Director, Chief Executive OfficerMr. Pascal Soriot
Non-Executive DirectorMr. Philip A J Broadley
Non-Executive Director, Senior independent DirectorMr. Graham Andrew Chipchase
Non-Executive DirectorProfessor Genevieve Berger
Non-Executive DirectorMs. Deborah DiSanzo
Non-Executive DirectorProfessor Nazneen Rahman
Non-Executive DirectorProfessor Tony Mok
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.